Ameritox Launches New Method to Help Assess Medication Non-Adherence for Patients Prescribed Top-Selling Drug Abilify

BALTIMORE, March 17, 2014 /PRNewswire/ -- Ameritox^SM, the nation's leader in medication monitoring solutions, introduced a new method to assist physicians in assessing medication non-adherence for patients with serious mental illness prescribed the antipsychotic drug Abilify, the top-selling medication in the U.S.

Based on a research study of patients administered Abilify, Ameritox established an independent benchmark that can provide additional information about whether a patient may be taking this powerful and widely prescribed medication correctly. By comparing urine drug results against this baseline study, behavioral health centers and medical professionals have more information as they assess, manage and treat patients prescribed Abilify. Results from the preliminary pilot study describing urine metabolites found in patients taking Abilify were published in the February issue of the Journal of Pharmacology and Clinical Toxicology. Additional studies are underway to develop similar benchmarks for other antipsychotic drugs.

"We are applying our data-driven approach toward pain-medication monitoring to the substantial problem of medication non-adherence among patients diagnosed with mental illness," said Ameritox Chief Executive Scott Walton. "Our ability to reliably test for antipsychotic medications such as Abilify can improve patient care while helping to prevent the human tragedy too often associated with medication non-adherence."

Without a simple, non-invasive procedure like a urine drug test, doctors previously faced challenges in evaluating whether a patient was taking a medication such as Abilify. The problem of those with mental illness not taking their medication is acute: Studies show at least 50% of patients with serious mental illness go unmedicated each year because of failure to take prescribed medication.

"It is not too often that a simple tool comes along to help physicians assess potential non-adherence by their patients with these powerful medications," said Dr. Robert Millet, director of clinical research at Carolina Behavioral Care and adjunct faculty member at Duke University Medical Center in Durham, North Carolina. "This is a big advancement towards helping our patients, their families and the communities we serve."

The patient and societal consequences of untreated serious mental illness are enormous and include violence, homelessness and incarceration. In the U.S., about 13,000 suicides and half of the mass killings each year are committed by those with untreated serious mental illness, according to the Treatment Advocacy Center, a national nonprofit organization focused on treatment of serious mental illness.

"Medication monitoring is a critical component in treating serious mental illness," said Dr. Kenneth Dretchen of the Department of Pharmacology and Physiology at Georgetown University Medical Center, who participated in the study. "Being able to help physicians assess patient non-adherence to the medication prescribed can help prevent overdoses or reduce dangerous side effects. In the end, patients can enjoy fuller lives knowing that the drug will help them recover."

The full study can be found here.

About Ameritox
Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As the nation's trusted leader in Pain Medication Monitoring Solutions^SM, Ameritox provides medical and business professionals with data-driven analysis and tailored solutions that can improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has 800 employees nationwide and laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox
Watch Ameritox on YouTube: www.youtube.com/ameritox

SOURCE Ameritox